Log in

Stock viewCNBC-TV18

Glenmark shares rise after US arm launches cancer therapy

Positive+24

GreyOak summary

Glenmark Pharma shares gained up to 2% after its US arm launched a generic version of INLYTA tablets for kidney cancer treatment. The drug, originally developed by Pfizer, targets advanced disease cases.

What it affects

Source

Read the original at CNBC-TV18

More Glenmark Pharmaceuticals news

All Glenmark Pharmaceuticals news →